ERA4TB (DIT.AD021.106)

Area tematica

Ingegneria, ICT e tecnologie per l'energia e i trasporti

Area progettuale

Struttura responsabile del progetto di ricerca

Istituto per le applicazioni del calcolo "Mauro Picone" (IAC)

Responsabile di progetto

PAOLO TIERI
Telefono: 0649937349
E-mail: p.tieri@iac.cnr.it

Abstract

The European Tuberculosis Regimen Accelerator (ETBRA) has the explicit goal of developing a new combination therapy to treat all forms of TB starting from ~20 leads and drug candidates provided by EFPIA. Since details of these are as yet unavailable, we will implement an agile drug development algorithm that entails profiling and portfolio construction. Profiling involves characterisation and ranking molecules in preclinical studies comprising in vitro drug combination assays, hollow fiber and single cell analysis, innovative murine and non-human primate models, PK/PD studies, combined with biomarker discovery and non-invasive NIR or PET/CT imaging to monitor disease progression and response to treatment. Modelling, simulation and artificial intelligence tools will help progress compounds from early preclinical to clinical development and to predict drug exposure, human doses and the best combinations. After extensive preclinical profiling, selected compounds will enter portfolio development for first time in human tests and phase I clinical trials in order to ensure that they are safe, well-tolerated and bioavailable with negligible drug-drug interactions. If needed, formulation s

Obiettivi

sviluppo ed implementazione di modellistica avanzata per il trattamento della tubercolosi.

Data inizio attività

01/01/2020

Parole chiave

modellistica, tubercolisi

Ultimo aggiornamento: 05/05/2024